ProCE Banner Activity


Pathology Master Class: Targeting Genomic Alterations for Personalizing Lung and Thyroid Cancer Care


In this on-demand webcast from a live symposium at ASCP 2022, pathology experts provide guidance on best practices for detection of targetable gene alterations in advanced non-small-cell lung cancer and thyroid cancer, including discussion of the latest clinical evidence for targeting disease with a RET alteration or NTRK fusion.

US Physicians : maximum of 0.50 Medical Knowledge MOC point(s)

ABPath MOC : maximum of {0:0.0#} Lifelong Learning (Part II) and Self-Assessment Module (SAM) point(s)

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: October 24, 2022

Expiration: October 23, 2023



Jeremy P. Segal

Jeremy P. Segal, MD, PhD

Associate Professor
Department of Pathology
Molecular and Cytogenetic Pathology
University of Chicago
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


ASCP -Clinical Pathology

ProCE Banner

Target Audience

This program is intended for medical oncologists, pathologists, endocrinologists, surgeons, interventional radiologists, and other healthcare professionals who care for patients with lung or thyroid cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Order appropriate assays or molecular tests to detect oncogenic gene fusions in patients with NSCLC and thyroid cancer
  • Appraise emerging clinical data supporting the use of TRK inhibition in NTRK fusion–positive NSCLC and thyroid cancer and RET inhibition in RET-altered lung and thyroid cancer
  • Refer eligible patients with NTRK fusion–positive and RET-altered NSCLC and thyroid cancer for ongoing clinical trials


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Jeremy P. Segal, MD, PhD

Associate Professor
Department of Pathology
Molecular and Cytogenetic Pathology
University of Chicago
Chicago, Illinois

Jeremy P. Segal, MD, PhD: consultant/advisor/speaker: AstraZeneca, Bayer.

Staff Disclosure


Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant financial relationships to disclose.

Marie Cavalier Rush, PharmD, BCOP

Marie Cavalier Rush, PharmD, BCOP, has no relevant financial relationships to disclose.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant financial relationships to disclose.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant financial relationships to disclose.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant financial relationships to disclose.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant financial relationships to disclose.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.

Instructions for Credit


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to maximum of 0.5 Lifelong Learning points in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 24, 2022, through October 23, 2023:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65.00% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.



The goal of this activity is to improve the knowledge, competence, and performance of learners to assess new and emerging biomarkers and planning individualized treatment for patient with lung or thyroid cancers.